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Abstract: Obesity caused by overnutrition is a major risk factor for non-alcoholic fatty liver disease
(NAFLD). Several lipid intermediates such as fatty acids, glycerophospholipids and sphingolipids are
implicated in NAFLD, but detailed characterization of lipids and their functional links to proteome and
phosphoproteome remain to be elucidated. To characterize this complex molecular relationship, we
used a multi-omics approach by conducting comparative proteomic, phoshoproteomic and lipidomic
analyses of high fat (HFD) and low fat (LFD) diet fed mice livers. We quantified 2447 proteins and
1339 phosphoproteins containing 1650 class I phosphosites, of which 669 phosphosites were significantly
different between HFD and LFD mice livers. We detected alterations of proteins associated with
cellular metabolic processes such as small molecule catabolic process, monocarboxylic acid, long- and
medium-chain fatty acid, and ketone body metabolic processes, and peroxisome organization. We
observed a significant downregulation of protein phosphorylation in HFD fed mice liver in general.
Untargeted lipidomics identified upregulation of triacylglycerols, glycerolipids and ether
glycerophosphocholines and downregulation of glycerophospholipids, such as lysoglycerophospholipids,
as well as ceramides and acylcarnitines. Analysis of differentially regulated phosphosites revealed
phosphorylation dependent deregulation of insulin signaling as well as lipogenic and lipolytic pathways
during HFD induced obesity. Thus, this study reveals a molecular connection between decreased protein
phosphorylation and lipolysis, as well as lipid-mediated signaling in diet-induced obesity.
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1. Introduction
Obesity is a prevalent health concern worldwide, and it is accompanied by a plethora of
comorbidities. Among them, non-alcoholic fatty liver disease (NAFLD) is now recognized
as the most common form of liver disease, affecting one quarter of the global population,
which has a similar rate of prevalence as obesity [1]. NAFLD is characterized by fat
accumulation in the liver that is not caused by alcohol consumption, and is associated with
different factors, including an increase in dietary fat released from adipocytes via lipolysis,
de novo hepatic lipogenesis, circulating free fatty acid (FFA) and a decrease in fatty acid
oxidation [2,3]. NAFLD poses a significant health burden because even the earliest and
most common type of NAFLD, simple steatosis, is shown to be not as prognostically benign
as it has been thought for a long time. As an illustration, a recent large-scale cohort study of
10,568 patients with NAFLD in Sweden found that patients with simple steatosis showed a

Cells 2022, 11, 1172. https://doi.org/10.3390/cells11071172

https://www.mdpi.com/journal/cells

Cells 2022, 11, 1172

2 of 22

significantly elevated risk of extrahepatic cancer, hepatocarcinoma, cardiovascular disease
and cirrhosis [4]. Therefore, it is critical to understand the molecular signatures involved in
the onset of steatosis as the failure of proper liver functions will promote pathogenesis of
metabolic complications in turn [5].
HFD feeding is advantageous for the establishment of fatty livers in mice as it generates
less pronounced inflammation and rarer fibrosis after an extended period of intervention
than in the case of a methionine-choline deficient diet [6,7]. Moreover, the model establishes
pathologic phenotypes resembling human disease as it is accompanied by obesity, insulin
resistance and hyperlipidemia [6,7]. Therefore, the diet-induced obesity (DIO) is typically
associated with complex and intertwined metabolic abnormalities that primarily entail
the involvement of a multitude of proteins, including their differential expression, posttranslational modifications, and protein–protein interactions [8–10]. Similar to proteins,
lipids also have extensive biological roles as signaling molecules, energy reserves and structural components of membranes. Gaining information about regulation/dysregulation
of each class of lipids in response to DIO and integrating these results with proteomics
and phosphoproteomics is important for our comprehensive understanding of the etiology
of fatty liver. In the last three decades, significant progress has been made in our understanding of the wide-ranging changes in proteins, RNA and metabolites caused by obesity
and overnutrition [8,9,11–13]. However, most of the omics studies on obesity and insulin
resistance thus far have focused on one area (either proteomics or lipidomics), and only
a few have focused on multi-omics approaches. Studies integrating global proteomics,
phosphoproteomics and lipidomics of liver under the context of DIO are limited. Such
integrated analyses, however, can be a powerful strategy to depict the changes in cellular
functions controlled by highly connected protein and lipid molecules. This knowledge
could be particularly useful for understanding the biology of obesity-related pathologies,
and for the development of new treatment strategies.
In the present study, we aimed to explore the changes in liver proteins and lipids
and their functional role and relationship in the development of DIO at systems level
by performing an integrative multi-omics analysis and correlating identified modules
with DIO.
2. Materials and Methods
2.1. Mouse Husbandry and Diets
All procedures involving animals were performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals and were reviewed and
approved by the Purdue Animal Care and Use Committee (protocol number 1111000154).
C57BL/6 male mice were kept in a humidity and temperature-controlled facility in a 12:12 h
dark/light cycle with ad libitum access to food and water. From weaning to 5 weeks of
age, mice were fed a chow diet consisting of 62.1% of calories from carbohydrate (starch),
24.7% from protein, and 13.2% from fat (PicoLab 5053, Lab Diets, Richmond, IN, USA).
At 5 weeks of age, mice were randomly assigned to one of the two diets for an additional
12 weeks: low-fat diet (LFD, 10% of calories from fat, D12450J) or high-fat diet (HFD, 60%
of calories from fat, D12492) (Research Diets, Inc., New Brunswick, NJ, USA). Body weight
was recorded weekly. Fasting blood glucose was measured using the OneTouch glucometer (LifeScan, Milpitas, CA, USA). After 12 weeks, mice were fasted for two hours and
euthanized by CO2 followed by cervical dislocation and livers were collected and stored at
−80 ◦ C for further analysis. Fat pad weight was measured at the time of euthanasia.
2.2. Liver Tissue Preparation for Proteomics
Livers from six lean mice and six DIO mice were homogenized in 100 mM of ammonium bicarbonate, supplemented with protease and phosphatase inhibitors, in a Precellys
Evolution, using CK14 soft tissue homogenizer tubes (Bertin Technologies SAS, Montignyle-Bretonneux, France) for 3 × 20 s bursts at 6200 rpm. The protein concentration of each
homogenate was determined by bicinchoninic acid assay kit (Thermo Fisher Scientific). An
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aliquot of each sample containing 500 µg of total protein was precipitated using ice-cold acetone at −20 ◦ C overnight. After acetone removal, protein pellets were reduced with 10 mM
dithiothreitol in 8 M urea, and alkylated using iodoethanol in ACN (2% iodoethanol, 0.5%
triethylphosphine, 97.5% acetonitile). The proteins were digested with mass spec grade
Trypsin/LysC mix (Promega, Wisconsin, WI, USA) at a 1:50 (w/w) enzyme-to-substrate
ratio, using a barocycler (Pressure BioScience Inc., Easton, MA, USA) at 50 ◦ C with 60 cycles
of 20 kpsi for 50 s and 1 atmospheric pressure (1 ATM) for 10 s, following the Hedricks et al.
protocol [14]. Samples were cleaned using Pierce Peptide Desalting Spin Columns (Thermo
Fisher Scientific, Waltham, MA, USA). Samples were then divided into two tubes containing
50 µg and 450 µg peptides. The 450 µg peptides were further processed for phosphopeptide
enrichment by using the PolyMac phosphopeptide enrichment spin-tips (Tymora Analytical, West Lafayette, IN, USA), following the manufacturer’s recommendations. Finally,
samples were dried and resolubilized in 20 µL 0.1% formic acid (FA) in 3% acetonitrile
(ACN) and 1 µg was loaded into the column for global profiling. Purified phosphopeptides
were re-suspended in 10 µL of 0.1% FA in 3% ACN and 5 µL for phosphoproteomics.
2.3. Mass Spectrometry Analysis of Liver Proteome
Samples were analyzed by reverse-phase LC-ESI-MS/MS system using the Dionex UltiMate 3000 RSLC nano System, coupled to a Q-Exactive High-Field (HF) Hybrid Quadrupole
Orbitrap MS (Thermo Fisher Scientific) as described previously [13]. Briefly, peptide
separation was accomplished using a trap column (300 µm ID × 5 mm) packed with
5 µm 100 Å PepMap C18 medium, and then using a reverse phase analytical column
(50-cm long × 75 µm ID), packed with 2 µm 100 Å PepMap C18 silica (Thermo Fisher Scientific, Waltham, MA, USA). The column was maintained at 50 ◦ C, mobile phase solvent
A was 0.1% FA in water, solvent B was 0.1% FA in 80% ACN and the loading buffer was
0.1% FA in 2% ACN. Peptides were solubilized in 0.1% FA in 3% ACN and loaded into
the trap column in the loading buffer for 5 min at 5 µL/min, then separated with a flow
rate of 150 nL/min using a 224.9 min linear gradient from 2% to 30% B, then changing
to 60% B at 260 min before reverting to 2% B for re-equilibration for 20 min. The mass
spectrometer was operated in positive ion and standard data dependent acquisition mode.
The spray voltage was set at 2.6 kV, the capillary temperature was 320 ◦ C and the S-lens
RF level was set at 50. The resolution of Orbitrap mass analyzer was set to 120,000 and
15,000 at 200 m/z for MS1 and MS2, respectively, with a maximum injection time of 100 ms
for MS1 and 20 ms for MS2. The full scan MS1 spectra were collected in the mass range of
350–1600 m/z and the MS2 first fixed mass was 100 m/z. The automatic gain control (ACG)
target was set to 3 × 106 for MS1 and 1 × 105 for MS2. The fragmentation of precursor ions
was accomplished by higher energy C-trap collision dissociation (HCD) at a normalized
collision energy setting of 27% and an isolation window of 1.2 m/z. The data dependent
acquisition settings were for top 20 MS2 with a minimum intensity threshold of 5 × 104
and a minimum AGC target of 1 × 103 . The dynamic exclusion was set at 15 s and accepted
charge states were selected from 2 to 7 with 2 as a default charge. The exclude isotopes
function was activated.
2.4. Data Analysis
LC–MS/MS data were processed with MaxQuant software (Ver 1.6.17.0) [15,16]. Raw
spectra were searched against the mouse UniProt FA Mus musculus protein database (June
2021). Six amino acids were set as the minimum length required in the database search. The
search was performed with a precursor mass tolerance of 10 ppm and MS/MS fragment ions
tolerance of 20 ppm. Trypsin and LysC were set as specific enzymes, with up to two missed
cleavages allowed. Oxidized methionine, and for the phosphoproteomics, phospho STY
were defined as a variable modification, and iodoethanol of cysteine was defined as a fixed
modification. The “unique plus razor peptides” were used for peptide quantitation and
the false discovery rate of peptides spectral match and protein identification was set at 1%.
“Label free quantitation” (LFQ) and “Match between runs” were enabled. Subsequent bioin-
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formatic analysis was performed with Perseus (version 1.6.7.0) [17]. Proteins labeled “only
identified by site”, “reverse”, or “contaminants” were removed from the analysis. Proteins
were filtered for at least five valid values among six biological replicates (70%) in either of
the conditions. Missing values were replaced by values derived from a normal distribution.
Significantly up- or downregulated proteins between the two groups were determined by a
Student’s t-test with Permutation-based FDR (q-value < 0.05, |log2 (fold-change)| > 0.38).
For phosphoproteomics, only class one phosphosites (localization probability > 0.75) were
considered for downstream analysis. Functional annotations and enrichment analysis were
performed using Metascape. Volcano plots were generated with the EnhancedVolcano R
package [18].
2.5. Lipid Extraction and Measurement
Lipids were extracted using the Bligh and Dyer extraction method [19]. Briefly, 200 µL
of liver homogenates with an equal amount of protein were transferred to a new tube and
mixed with 550 µL of methanol and 250 µL of chloroform. The solution was vortexed
briefly and incubated at 4 ◦ C for 15 min, 250 µL of ultrapure water and 250 µL of chloroform
were added and the sample was centrifuged for 10 min at 16,000× g, forming a 2-phase
solution. Bottom organic phase was transferred to a new tube and dried and samples were
stored at −80 ◦ C until analysis. Lipid extracts were analyzed in an Agilent 1290 Infinity II
UPLC, coupled to an Agilent 6545 quadrupole time-of-flight tandem mass spectrometer.
Samples were resuspended in 30 µL of a mixture of ACN: methanol: water (3:5:2 v/v)
and 8 µL were loaded to a Waters ACQUITY UPLC® BEH C18 1.7 µm column with a
controlled temperature of 45 ◦ C. The binary pump used 10 mM ammonium acetate in
water with 0.1% FA for mobile phase A and 10 mM ammonium acetate in a 50% isopropyl
alcohol: 49.9% ACN: 0.1% FA for mobile phase B, at a flow rate of 0.4 mL/min. The liquid
chromatography gradient was of 35% B at 0 min, 80% B at 5 min and ramped up to 100% B
at 10 min, with a 5 min hold, then returned to 35% B in 2 min and a 4 min hold. The mass
analyzer was set with a ESI capillary voltage of 35,000 Vcap, a sheath gas temperature of
320 ◦ C and flow of 8 L/min, a nebulizer gas pressure of 35 psig, a fragmentor of 135 Vs
and skimmer of 35 V. Mass spectrums were collected in profile mode with a range from 100
to 1200 m/z at a scan rate of 5 spectra/s with 200 min/spectrum for MS1 and 3 spectra/s
with 333.3 mS/spectrum for MS2. Raw data were processed using MS-dial 4.7 [20] with the
MSP spectral kit of 13,303 unique compounds in positive mode.
A second lipid extract obtained as described above was used for fatty acid methylations
(FAMEs) to analyze free fatty acid content by GC–MS. Before derivatization, the samples
were spiked with 1 µg of C17:0 as internal standard. The samples were derivatized with
500 µL of 14% boron trifluoride solution (Sigma-Aldrich # B1252) and reacted for 30 min
at 60 ◦ C, followed by the addition of 500 µL of water and 500 µL of hexane. After mixing,
0.2 g of anhydrous sodium sulfate was added to the sample, and it was allowed to sit. The
hexane layer was collected and dried. GC–MS derivatized samples were resuspended in
100 µL of 100% hexane in a Thermo Fisher Triplus RSH auto sampler and Trace 1310 gas
chromatography (GC) system, coupled to a Thermo Fisher TSQ 8000 mass spectrometer
(MS) (Thermo Fisher Scientific, Waltham, MA, USA), with an Agilent Select FAME GC
column (50 m × 0.25 mm, film thickness 0.2 um) (Agilent Technologies, Santa Clara, CA,
USA). The GC carrier gas was helium with a linear flow rate of 1.5 mL/min. The GC
temperature gradient started at 70 ◦ C at 0 min and was ramped up to 310 ◦ C at 7 ◦ C/min
and held for 1 min for a total run time of 38.28 min. The GC inlet was set to 250 ◦ C and
samples were injected in split mode with a ratio of 10 and a flow of 15 mL/min. The
MS transfer line was set to 250 ◦ C and the MS ion source was set to 250 ◦ C. MS data
were collected in selected ion monitoring (SIM) mode. Raw data were analyzed with
Thermo Fisher Chromeleon (Version 7.2.9) software and a standard mixture of 37 FAME
(Sigma-Aldrich Corp., St. Louis, MO, USA) was used to confirm spectra and column
retention times.
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Thus, to categorize and characterize the proteins significantly regulated during DIO,
we performed a Gene Ontology (GO) enrichment analysis of both upregulated and downregulated proteins together. Notably, several GO terms were listed as both downregulated
and upregulated, such as monocarboxylic acid and metabolic process, small molecule
biosynthetic process, sulfur compound metabolic process and others, which likely indicate
a wholistic metabolic reprograming of such processes where specific subsets of proteins
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Figure 4. Gene ontology analysis of significantly regulated proteins. (A) Metascape enrichment
analysis of statistically enriched GO Biological Process (BP) terms. The terms were selected with
the best p-value within each cluster as its representative term. (B) Enriched clusters’ GO-BP terms
in network format. Each enriched term is displayed as a circle node whose size is proportional to
the number of input proteins that fall into the term. Each node is represented as a pie chart and
each pie sector is proportional to the number of hits originated from either up- or downregulated
proteins. (C) Enrichment of transcriptional regulators of significantly regulated proteins using
TRRUST (transcriptional regulatory relationships unraveled by sentence-based text-mining) database.
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3.3. Differentially Expressed Phosphoproteins in the Liver from HFD and LFD Fed Mice
Protein phosphorylation is a major driver of protein function, protein localization
and protein–protein interactions [36,37]. Thus, to gain an insight on how proteins are
regulated during DIO in a larger scope, which transcends the changes in protein levels
alone, we performed a comprehensive phosphoproteomic analysis of the liver tissues in
which the global analysis was performed. We identified a total of 1391 phosphoproteins,
containing 1650 class I phosphosites (phosphosites with localization probability > 0.75).
We also observed 14 novel phosphosites on the proteins Eif3m, Ubxn, Atf7, Reps2, Gprin3,
Tacc2, Igf1r, Gsr, Ubxn7, Snx11 and Abcb11 (Supplementary Materials Table S2). Of the
1650 class I phosphosites, 1517 (92%) sites were serine, 124 (7.5%) sites were threonine
and 9 (0.5%) were tyrosine phosphorylated. Of these 1650 phosphosites, 669 sites were
significantly different between HFD and LFD fed mice; 15 were upregulated and the
remaining were downregulated (Supplementary Materials Table S2). This result suggests
a significant decrease in site-specific phosphorylation in HFD fed mice, highlighting the
changes in protein regulatory mechanisms in mice due to DIO. Increased phosphosites
in HFD were observed in transporter proteins such as sodium bicarbonate transporter
(Slc4a4), solute carrier anion transporter (Slco1b2), helicase ARIP4 (Rad54l2), RNA binding
protein (Rbm39), and glycerol-3-phosphate acyltransferase (Agpat9). Of the nine tyrosine
phosphorylation sites, six were significantly different with one increased (Slc4a4) and five
decreased (Gsk3a, Gpxl, Uox, Mapk14 and Arhgap35) phosphorylation levels. Further, five
of the nine tyrosine phosphorylation sites belonged to proteins containing known kinase
domains (Mapk1, Mapk14, Gsk3a and 3b, Dyrk1a and 1b, and Prpf4b; Supplementary
Materials Table S2), and the phosphorylation levels of all these sites decreased in HFD
mice liver. We also identified an additional six phosphoproteins with known kinase
domains, and all showed decreased phosphorylation at serine and threonine residues. A
predominant decrease in phosphorylation is easily visualized as a heatmap (Figure 5A)
and further evidenced by a volcano plot, representing all filtered phosphosites, in which
samples corresponding to HFD are marked by the consistent downregulation of thousands
of phosphosites (Figure 5B).
Several solute career (Slc) transporters including Slc2a2, Slc10a1, Slc16a1, Slc16a10,
Slc16a7, Slc33a1, Slc38a4, Slc4a1, Slc4a4, and Slc4a10 had downregulated phosphosites
in HFD fed mice liver (Supplementary Materials Table S2). Although several of these
transporters were also downregulated at the protein level, their phosphosite level downregulation was greater. These transporters facilitate the transport of substrates across cell
membranes, including glucose, inorganic and organic ions, small molecule drugs, xenobiotics and amino acids, and contribute to insulin signaling, glucose homeostasis and the
etiology of different metabolic diseases [38,39]. The glucose transporter isoform, Glut2
(known as Slc2a2), was phosphorylated at serine 522, and phosphorylation decreased
in HFD compared to LFD mice liver (Supplementary Materials Table S2). Glut2 expression was also down at the protein level, suggesting impaired glucose homeostasis and
dysregulated insulin response. Other notable downregulated solute transporters were
lactate and H+ transporter, Slc16a1; acetyl-CoA transporter, Slc38a1; sodium and amino
acid transporter, Slc33a1; and sodium and bile acid transporter, Slc10a1. We also identified
downregulation of acetyl-CoA carboxylase (Acaca and Acacb), both at the protein and
phosphosite levels (Supplementary Materials Table S2), and again, downregulation at the
phosphorylation level was greater than at the protein level. Acaca was phosphorylated
at serine 23, 29 and 79, whereas Acacb was phosphorylated at serine 1332. The decreased
phosphorylation of the enzymes in all these phosphosites under the HFD fed condition
further indicates dysregulation of lipogenesis and glucose homeostasis.
GO enrichment analysis of proteins regulated at their phosphosite levels indicated
that RNA metabolism was highly affected by HFD. Interestingly, we also found that cellular response to insulin stimulus was one of the top 20 most significant downregulated
processes among the enriched phosphoproteins (Figure 5C). Many other biological processes, as expected from previous studies on diet-induced obesity [8,40,41], are related to
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communication, protein localization, apoptotic signaling, and oxidative stress responses
(Figure 5C).
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3.4. Differentially Expressed Lipids in the Liver from HFD and LFD Fed Mice
Recent studies have reported that the tumor suppressor, promyelocytic leukemia
Proteome and phosphoproteome analysis alone might not reflect the changes in the
(PML) protein, plays a regulatory role in cellular metabolism, by controlling Ppar, which,
lipid content of the liver. To directly investigate the changes in lipid composition and regin turn, is involved in an important signaling pathway that modulates lipid homeostaulation at the metabolite level due to HFD, we conducted an untargeted global lipidomics
sis [40,41]. PML is known as the key organizer of the PML-Nuclear Bodies (PML-NBs), and
using LC–MS and GC–MS analytical systems. Untargeted lipid profiling detected a total
has fascinated scientists for many years due to its multifaceted role under many cellular
of 3728 lipid
ions present
in at least 80%
of one group.
using
MS-Dial
conditions,
notably
acute promyelocytic
leukemia
[42,43].Data
Liverprocessing
PML ablation
induces
exallowed for the tentative identification of 1801 features after blank filter. A total of 464
lipid ions had MS2 acquired data and were used for statistical analysis (Supplementary
Materials Table S3). Most lipids detected were triacylglycerols (TAGs) and phosphatidylcholines (PCs), followed by diacylglycerols (DAGs) and sphingolipids. Several lipids were
suggested with Riken IDs and grouped as unknowns. FAMEs (hereon called FFA) were
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tensive reprograming of metabolic pathways, including an accelerated fatty acid metabolic
rate accompanied by decreased total lipid accumulation in the liver, as well as insulin
resistance [44]. To investigate the effects of HFD in PML-NB proteins, we constructed a
library using protein–protein interaction databases and filtered for the proteins identified
in our global and phosphoproteomics study. Many well-known PML-NB proteins were
identified and were regulated at their protein and/or phosphosite levels (Figure 5D), including the protein PML. Phosphorylation of PML was downregulated, notably at S17,
a phosphosite targeted by the kinase Cdk. (Supplementary Materials Table S2). Further,
phosphosites belonging to several E3 sumo and ubiquitin ligases were also identified and
were downregulated in the HFD mice liver compared to the LFD mice liver, including
RanBP2, Nedd4, Praja-1, Rbbp6, Urb4, and Zfp19 (Figure 5D). These results suggest that
not only protein phosphorylation, but protein SUMOylation and ubiquitination may also
be regulated in response to DIO. It is important to mention that decreases in the phosphorylation of the majority of the PML-NB proteins was independent of the relative changes in
protein abundances.
3.4. Differentially Expressed Lipids in the Liver from HFD and LFD Fed Mice
Proteome and phosphoproteome analysis alone might not reflect the changes in
the lipid content of the liver. To directly investigate the changes in lipid composition
and regulation at the metabolite level due to HFD, we conducted an untargeted global
lipidomics using LC–MS and GC–MS analytical systems. Untargeted lipid profiling
detected a total of 3728 lipid ions present in at least 80% of one group. Data processing using MS-Dial allowed for the tentative identification of 1801 features after blank
filter. A total of 464 lipid ions had MS2 acquired data and were used for statistical
analysis (Supplementary Materials Table S3). Most lipids detected were triacylglycerols
(TAGs) and phosphatidylcholines (PCs), followed by diacylglycerols (DAGs) and sphingolipids. Several lipids were suggested with Riken IDs and grouped as unknowns. FAMEs
(hereon called FFA) were identified using GC–MS and normalized to C17 internal standard
(Supplementary Materials Table S4). Lipid data were centered at the mean and divided
by the standard deviation of each variable to scale them and account for the difference in
intensities in the subsequent analysis.
Unsupervised PCA analysis of the lipid features’ relative intensities revealed clear
separation of the two groups with 42.4% of explained variance (Figure 6A). The heatmap
illustrates the difference in the detected lipid profile of each sample and shows two main
clusters with opposite trends (Figure 6B). Univariate analysis comparing the lipid profiles
of HFD and LFD fed mice identified 109 lipid features with p-values below 0.05 after the
t-test, and 42 features with reduced and 67 features with increased relative amounts of at
least 2-fold-change, which are represented in the volcano plot (Figure 6C). As expected,
TAGs and FFA were increased in the HFD compared to the LFD and most PCs, PE and
LPCs were decreased. Lipid ontology (LION) enrichment [45] was performed for lipid
class overrepresentation analysis (Figure 6D), and showed upregulated TAGs, followed by
glycerolipids and ether glycerophosphocholines. On the other hand, glycerophospholipids,
including lysoglycerophospholipids and ceramides were significantly downregulated.
Although not overrepresented, unusual acylcarnitines CAR (24:6) and CAR (28:6) were
significantly downregulated. Glycerophosphoglycerols, such as BMP (35:4) and HBMP
(48:0), were significantly reduced in the HFD compared to the LFD despite not being largely
represented. LION analysis for cellular component, function, and physical and chemical
properties (Figure 6E), showed that lipid storage and lipid droplet formation associated
lipids were significantly increased in DIO mice, as well as lipids with neutrally charged head
groups. In addition, 12 to 22 carbon fatty acids either saturated, monounsaturated or with
more than three double bonds were increased, while 24 to 26 carbon fatty acids with two and
three double bonds were reduced compared to LFD. Lipids linked to endoplasmic reticulum
(ER) and lipid-mediated signaling were significantly reduced in the HFD compared to the
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LFD, as well as lipids associated with the membrane components, intrinsic curvature and
positive/zwitterion head group.
To derive insights on whether distinct lipid components align with the changes in
proteins or phosphoprotein profiles, correlations between detected lipid species and significantly changing proteins in the global and phosphoproteomics were analyzed. Lipids were
assigned to their respective classes, and the class correlation was obtained as described
by Chauhan et al. [46]. Variable importance in projection (VIP), which is defined as the
weighted sum of squares of the loadings in a partial least squares discriminant analysis,
that takes into account the amount of explained variation in each dimension, was used
to rank the features. Correlation heatmaps of global proteins and lipid classes showed
that glycerophosphoglycerols, ether-linked digalactosyldiacylglycerols, LPC, LPE, neutral
sphingolipids, and PS presented stronger correlation (p < 0.0 and VIP > 0.8) with the identified proteins, while triacylglycerols did not appear highly correlated with global proteins
(Figure 7A; Supplementary Materials Table S5). When examining the phosphoproteomics
correlation heatmap (Figure 7B; Supplementary Materials Table S6), fewer lipid classes had
significant correlation across the phosphosites identified. Ether-linked PC (EPC) and FFA
were predominantly negatively correlated with phosphosites, such as Tnks1bp1 (S796),
Chd4 (S508), Grb7 (S420), Acss2 (S263), and Bad (S155), while acylcarnitines, glycerophosphoglycerols, LPC and LPE were mostly positively correlated, with the exception of Thrap3
(S669), Agpat9 (S68), Hadh (S13), Pdha1 (S300), Prpf4b (S145), Rad54l2 (S1168 and S1171),
Rbm39 (S127 and S129), Rpap3 (S429), Scaf4 (S154), Slc4a4 (S68), Slco1b2 (S290), Sord (S169),
Srsf2 (S189 and S191), and Tnks1bp1 (S866) (Figure 7B). To gain insights on the potential
biological implications of strong correlation between certain lipid classes and phosphoproteins, significantly different proteins with a VIP larger than 1 that are in significant
correlation with lipids were analyzed using REACTOME for pathway analysis including
interactors. The identified significant pathways were comprised in the main categories
of metabolism, programmed cell death, signal transduction, transport of small molecules,
disease, and metabolism of proteins. Different pathways involved in energy metabolism
were highlighted such as glycolysis, gluconeogenesis, ChREBP activates metabolic gene
expression, and PKA-mediated phosphorylation of key metabolic factors, as well as PP2Amediated dephosphorylation of key metabolic factors (Figure 8A). Pathways related to
mitochondria function including activation of PPARGC1A (PGC-1α) by phosphorylation
and carnitine metabolism were also significantly enriched (Figure 8A). Several proteins
were grouped under translation by ribosomal scanning and start codon recognition and
signaling by Rho GTPases (Figure 8A). Interestingly, when individual phosphorylation
sites classified under certain pathways were categorized by correlation coefficient with each
lipid class (Figure 8B), it was evident that not all the phosphosites had the same behavior.
For example, Eif3b had four different phosphosites that meet the correlation cut-off criteria,
but each one of those sites showed different correlations with AC, FFA, Ether-PC, LPC
and LPE, highlighting the specificity of phosphosites and their unique regulation within a
protein. Another similar example is membrane protein Slc4a4. Slc4a4 (S68) had a negative
correlation with phospholipids, but such a relationship was not observed with Slc4a4 (Y64).

Cells 2022, 11, 1172

phosphosites that meet the correlation cut-off criteria, but each one of those sites s
different correlations with AC, FFA, Ether-PC, LPC and LPE, highlighting the spe
of phosphosites and their unique regulation within a protein. Another similar exam
membrane protein Slc4a4. Slc4a4 (S68) had a negative correlation with phospholipi
12 of 22
such a relationship was not observed with Slc4a4 (Y64).

Figure 6.
Lipid
(A) (A)
PCA
plot
biological
replicate.
(B) Heatmap
representatio
Figure
6. profiles.
Lipid profiles.
PCA
plotofofeach
each biological
replicate.
(B) Heatmap
representation
of all significantly
lipids.
Red indicated
upregulated
lipidspecies,
species, and
blue
indicated
significantly
changing changing
lipids. Red
indicated
upregulated
lipid
and
blue
indicated do
downregulated
lipid
species.
(C)
Volcano
plot
of
all
quantified
lipids.
(D)
Principal
lipid
classes
ulated lipid species. (C) Volcano plot of all quantified lipids. (D) Principal lipid classes cha
changed in the two groups. (E) Lipid ontology enrichment for function, cellular component and
chemical and physical properties significantly regulated.

Cells 2022, 11, 1172

Cells 2022, 11, 1172

13 of 22

13 of 22

the two groups. (E) Lipid ontology enrichment for function, cellular component and chemical and
physical properties significantly regulated.

Figure
7. Protein–Lipid
Pearsoncorrelation
correlation
matrix
between
38 lipid
classes
Figure
7. Protein–Lipidcorrelations.
correlations. (A)
(A) Pearson
matrix
between
38 lipid
classes
and and
255 255
significant
proteins,
phosphosites.
significant
proteins,and
and(B)
(B)649
649 significant
significant phosphosites.

Cells
2022,
11,11,
1172
Cells
2022,
1172

1414
ofof
2222

Figure8.8.Reactome
Reactomeenrichment
enrichmentofofcorrelation
correlationanalysis
analysis
forphospho
phospho
datasets.(A)
(A)Reactome
Reactomeenriched
enriched
Figure
for
datasets.
pathways
from
global
phosphoproteins
significantly
correlated
with
lipids.
(B)Correlation
Correlationanalysis
analysis
pathways
from
global
phosphoproteins
significantly
correlated
with
lipids.
(B)
of
phosphosites
of
interest,
categorized
by
enriched
reactome
pathway
and
lipid
classes.
of phosphosites of interest, categorized by enriched reactome pathway and lipid classes.

Cells 2022, 11, 1172

15 of 22

4. Discussion
Applying the multi-omics approach, we identified significant modulation of the liver
proteome and phosphoproteome involved in signaling, implicated in obesity and insulin
resistance. We observed decreased phosphorylation of the majority of identified phospho
STY sites in HFD fed mice, suggesting that metabolic disorders due to HFD induced obesity
are characterized by dysregulated phosphorylation-dependent signaling. Furthermore,
decreased site-specific phosphorylation of many protein kinases and key metabolic enzymes
involved in lipid and glucose homeostasis imply underlying functional consequences of
obesity and insulin resistance.
4.1. Altered Proteomes Related to Lipoprotein Assembly, Lipoprotein Uptake, De Novo Lipogenesis
(DNL) and Fatty Acid Uptake
The liver predominantly produces lipoproteins, other than chylomicron. DIO animals
had abundant apolipoproteins (ApoA4, ApoC1, ApoC2, ApoC4, ApoE, ApoH), which
indicates an increased level of circulating lipids. In terms of cellular uptake of blood lipids,
fatty acid uptake protein Cd36 was highly abundant in the livers of obese animals. A
previous study showed Cd36 null mice are protected from hepatic steatosis induced by
Lxr agonists and that Cd36 is a common target of Lxr, as well as Pparγ and pregnane X
receptor [47]. Although we did not identify Pparγ in global proteomic analysis, TRRUST
analysis revealed Pparγ as an enriched nuclear receptor that could explain significantly
upregulated proteins in DIO animals (Figure 4C). Furthermore, Lgals1, whose overexpression increases Pparγ protein level and transcriptional activation [29], was one of the most
upregulated proteins in DIO animals (Figure 3C) and was positively correlated with FFAs
having the highest VIP value. Evidence collectively suggests that the activation of Pparγ
played a major role in altered protein abundance involved in lipid metabolism in DIO.
Three key rate-limiting enzymes in de novo lipogenesis (DNL) (Acly, Acaca, Fasn),
as well as Scd1, that converts saturated fatty acids into monounsaturated fatty acids in
the final step of DNL, were present in lower amounts in the livers of the obese mice. Acly
was also found to be decreased in terms of phosphorylation at Ser455 in obese animals,
and the change in phosphorylation at this site was greater than the changes at its protein
levels, adding another layer of DNL attenuation, as phosphorylation at Ser455 is known
to increase Acly enzymatic activity [48]. On the other hand, despite a decreased Acaca
protein level (log2 (fold-change): −0.83677), diminished phosphorylation at the regulatory
site Ser79 was observed at a greater extent (log2 (fold-change): −1.289). This suggests that
Acaca is likely in an enzymatically active state, despite the decrease in its protein levels in
DIO, as phosphorylation is known to inhibit Acaca activity [49].
Other lipogenic enzymes such as desaturases that introduce double bonds in acyl
chains (Fads1, Fads2) and elongases which elongate C16 to longer acyl chains (Elovl2,
Elovl5) were identified, but did not show a difference between the lean and obese animals.
Meanwhile, lipid droplet proteins (Plin2, Plin4) were present in higher amounts in obese
animals, indirectly showing heightened lipid storage. Hepatic DNL is mainly controlled by
transcriptional regulation of genes by Srebp1 [50], Chrebp [51], liver X receptor α [52], and
Pparγ [53]. In agreement with these findings, Srebp1 and Chrebp were shown as enriched
transcription factors responsible for downregulated proteins, according to our TRRUST
analysis (Figure 4C). Overall, lipid accumulation in the livers of HFD fed animals is largely
attributed to an increased lipid flux rather than DNL.
Impaired glucose balance and insulin resistance characterize metabolic disorders in
DIO. There is growing evidence that Slc transporters contribute to the etiology of various
metabolic diseases [54]. Slc transporters are located in membranes and are highly expressed
in the liver, kidneys, heart, gut, and brain, and are emerging as potential drug targets [39].
They serve as a ‘metabolic gate’ in cells and mediate the transport of a wide variety of nutrients and metabolites such as glucose, amino acids, vitamins, neurotransmitters, inorganic
ions, organic anions, metals, and amino acids. Among the 35 identified Slc transporters,
the expression of 12 members showed significant changes between the HFD and LFD
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fed mice liver, of which 2 members (Slc22a1 and Slc25a10) had increased expression and
10 (Slc10a1, Slc25a11, Slc25a20, Slc25a22, Slc25a3, Slc2a2, Slc33a1, Slc6a13, Slc9a3r1, and
Slc01a1) had decreased expression. We identified several of these Slc transporters with
diminished site-specific phosphorylation in the HFD. This may suggest defects in insulin
signaling and transport of glucose and other molecules to membranes, essential for normal
cellular function. The transporter, Slc2a2, is responsible for the transport of glucose into
β-cells and facilitates glucose-mediated insulin secretion and signaling. Recessive mutation
of the Glut2 gene in mice showed hyperglycemia and abnormal glucose homeostasis [55].
Its downregulation and loss of phosphorylation in our study further suggest the impaired
utilization of glucose. However, the functions of other identified Slc transporters and the
consequences of their loss of phosphorylation in obesity are unknown.
4.2. Increased Mitochondrial Fatty Acid β-Oxidation, Ketone Body Formation
Intracellular fatty acids are activated by acyl-CoA synthetase before being channeled
into different metabolic fates, such as β-oxidation, triacylglycerol synthesis or phospholipid synthesis. Our results show Acsl1, a predominant isoform in the liver, was present
in the obese animals, increased below our cut-off threshold (log2 (fold-change): 0.306).
In sharp contrast, Acsl4 was significantly less abundant in the obese animals (log2 (foldchange): −1.478). Previous studies have shown arachidonic acid is a preferred substrate
for Acsl4 [56] and that Acsl4 protein expression is controlled by substrate induced posttranslational regulation, in which arachidonic acid promotes ubiquitin-proteasomal degradation [57]. Our fatty acid measurement (Supplementary Materials Table S4) shows a high
level of arachidonic acid in the livers of DIO animals, and this may have contributed in
part to reduced abundance of the protein. Other acyl-CoA synthetases with significant
fold-change include Acss3 (log2 (fold-change): 1.64) and Acss2 (log2 (fold-change): −0.97).
Acss3 is a mitochondrial enzyme whose expression is upregulated under ketogenic conditions [58], and our data show abundance in the livers of DIO animals. On the other hand,
Acss2 was not only less abundant, but also showed lower phosphorylation levels (Ser30,
Ser263, Ser267) in the livers of obese mice. Suppression of Acss2 in the liver after HFD
feeding was reported previously [59], and others have reported mice lacking Acss2 are
protected from steatosis induced by DIO [60]. This suggests that downregulation of Acss2
may serve as a defense mechanism against excess fat storage in the liver. However, it is
unclear how phosphorylation affects enzymatic activity and future study is warranted.
Our results are consistent with previous reports on the proteomic landscape of hepatic
steatosis by showing an abundance in proteins involved in mitochondrial β-oxidation.
Carnitine shuttling enzymes (Cpt1α, Slc25a20) were more abundant in the livers of obese
animals, transporting excess fatty acids from the cytoplasm into the mitochondrial matrix.
Acadm and Acad11 enzymes that catalyze dehydrogenation of fatty acyl-CoAs to form
enoyl-CoA were also more abundant in the obese animals, while the levels of Acadl were
not significantly different between the two groups. Acads and Acadvl were present at a
higher level in the livers of obese animals but did not meet our fold change cut-off value.
The enzymes that catalyze the hydration of the enoyl-CoAs (Ech1, Hadh) are abundant in
obese animals, with upregulation of Hadh Ser13 phosphorylation.
Hepatic ketogenesis occurs in the mitochondria and is activated to convert excess
acetyl-CoA generated from β-oxidation into ketone body intermediates. Several proteins
involved in ketogenesis were upregulated in the liver of the HFD fed animals: Bdh1;
Acat1; Hmgcs1,2; and Hmgcl. Aacs, that converts ketone bodies into acetoacetyl CoA for
cholesterol or fatty acid synthesis were less abundant in the HFD fed animals.
4.3. Increased Abundance of Proteins Involved in Peroxisomal β-Oxidation and
Microsomal ω-Oxidation
Peroxisomes are single membrane-enclosed subcellular organelles, particularly abundant in hepatocytes. One dynamic metabolic process that peroxisomes participate in is
the degradation of fatty acids that cannot occur in the mitochondria, specifically (1) very-
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long chain fatty acids with at least 22 carbons; (2) branched-chain fatty acids; (3) bile acid
intermediates such as di- and trihydroxycholestanoic acids; (4) long-chain dicarboxylic
acids [61]. Peroxisomal acyl-CoA oxidases that participate in catalyzing peroxisomal βoxidation (Acox1, Acox2, Acaa1a, Acaa1b), as well as the bifunctional protein, Ehhadh, that
catalyzes the hydration and dehydrogenation step of β-oxidation, were all upregulated in
the obese animals. Acyl-CoAs, that are produced during peroxisomal β-oxidation, can be
hydrolyzed into fatty acids by Acot4, or, alternatively, converted to carnitine esters and free
CoA by Crat and Crot, all of which were more abundant in HFD fed mice. Accordingly, our
results show that proteins involved in peroxisome biogenesis were abundant in the obese
mice, suggesting increased demand for the maintenance and biogenesis of the organelle
to support increased peroxisomal function. Peroxisome organization (GO:0007031) was
enriched uniquely in the livers of DIO animals (Figure 4A) and especially, proteins involved
in peroxisome biogenesis known as peroxins (Pex1, Pex11a, Pex16, Pex19, Pex3, Pex6) were
more present in the obese animals.
Another lipid catabolism pathway that increased in response to elevated hepatic
lipid overflow was microsomal ω-oxidation. The fatty acid ω-hydroxylases, Cyp4a10
and Cyp4a14, were highly upregulated in obese animals (Figure 3C). The resultant fatty
ω-hydroxy acids are catalyzed by two subsequent reactions by alcohol dehydrogenase
and aldehyde dehydrogenase. Our results show that microsomal fatty aldehyde dehydrogenase, Aldh3a2, was also more abundant in the obese animals. Overall, HFD feeding
stimulated mitochondrial, peroxisomal and microsomal fatty acid oxidation systems. The
fact that the key transcriptional factor, Pparα, is most enriched in DIO animals, according
to our TRRUST analysis (Figure 4C), further supports upregulation of β-oxidation in three
different subcellular organelles.
4.4. Decreased Glycolysis and Increased Gluconeogenesis
50 -AMP-activated protein kinase (AMPK) is an energy sensor kinase that activates
energy-producing pathways when the intracellular ATP level is low. In the livers of obese
mice, AMPK catalytic α-1 subunit, Prkaa1 (S496), had reduced phosphorylation, as well as
non-catalytic gamma subunits, Prkag2 (S71, S87, S90) and Prkab1 (S108, S96), indicating
reduced kinase activity. Prkag1 was also less abundant in the livers of DIO. Accordingly, we
identified that several proteins under AMPK regulation showed reduced phosphorylation
levels at specific sites in the obese animals. For example, glycogen synthase 2 (Gys2) phosphorylation at Ser8 (log2 (fold-change): −1.7954) and Ser 627 (log2 (fold-change): −4.591)
was downregulated in DIO, indicating the active state of the enzyme, favoring glycogen
synthesis despite a decreased protein level (log2 (fold-change): −0.7757).
Meanwhile, decreased phosphorylation states of glycolytic enzymes that are under the
control of AMPK induce glycolysis inhibition. Our data show downregulated phosphorylation of Pfkfb1 at Ser33, which indicates the activation of bisphosphatase and degradation
of fructose-2,6-biphosphate, favoring gluconeogenesis [62]. Moreover, reduced phosphorylation of Pfkl at Ser775 further supports increased gluconeogenesis by decreasing kinase
activity [63]. Carbohydrate response element-binding protein (ChREBP), which regulates
gene expressions involved in glycolysis, gluconeogenesis and DNL, is one of the main transcription factors enriched in our downregulated protein dataset (Figure 3C). Consistently,
our phosphoproteome results shows ChREBP phosphorylation was decreased at Ser514 in
DIO, the residue critical for maintaining the transcriptional activity of ChREBP by enhancing ChREBP O-GlcNAcylation via phosphorylation [64]. Accordingly, one of the ChREBP
target genes, Pklr, was less abundant in DIO animals, supporting decreased glycolysis.
4.5. Altered Abundance of Proteins Involved in ROS Scavenging
The influx of free fatty acids into hepatocytes leads to increased ROS, such as hydrogen
peroxide (H2 O2 ) and superoxide anion (O2 •− ) [65,66]. Our proteome results are consistent
with previous studies which show the induction of antioxidant systems in the steatotic
liver. Glutathione peroxidase 4 (Gpx4) is an enzyme found mostly in the mitochondria,
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which directly detoxifies membrane lipid peroxides at the expense of glutathione. Gpx4
was more abundant in the livers of HFD fed mice. Glutathione synthetase (Gss), that
replenishes glutathione from glycine and γ-glutamylcysteine, was also upregulated in DIO.
Furthermore, in our TRRUST analysis, Nrf2 was significantly enriched (Figure 4C). In DIO,
the glutathione-S transferases (Gst), targets of Nrf2, including Gstm1,2,3,4, Gstk1, Gsta1,4
and Gstt3, were more abundant. Another Nrf2 target, Nqo1, was also more abundant in
DIO animals. However, few Gst isoforms were less abundant in DIO: Gstm7; Gstp1,2; and
Gstt2, making cellular modified amino acid metabolic pathway (GO:0006575) a common
GO term in both the lean and DIO groups. A future investigation needs to identify the
biological significance of differential induction of multiple Gst isoforms during DIO.
4.6. Regulation of PML-NB Proteins under HFD
Although the role of PML as a tumor suppressor protein is well known, its role in
cellular metabolism, notably under obesity or HFD conditions, is unknown or inconclusive.
Carracedo and Pandolf [67] reported increased hepatic PML protein levels during liver
steatosis. The PML protein interferes with liver metabolism and controls fatty acid oxidation
in stem cells [68], and the depletion of PML in mice decreases liver fatty acid accumulation
after a long-term Western diet [44]. In contrast, other studies showed that PML inhibits
adipogenesis, and loss of PML results in fat accumulation in mice [40]. It is possible
that differences in a mouse strain, diets, aging, and environment may contribute to the
inconsistent phenotypes [44,69]. Our results also emphasize the role of PML in dietinduced obesity and cellular metabolism, and its regulation by phosphorylation. This
PML-dependent regulation may explain some of the inconsistencies reported in previous
studies, as none of those studies investigated the hepatic function of phosphorylated PML.
Downregulation of many E3 sumo and ubiquitin ligases also suggest the importance of
these modifications, and further highlight the regulation of PML and other NB proteins via
diverse modifications, as phosphorylation, SUMOylation and ubiquitination are known
to be interdependent to each other to execute cellular functions under various stressed
conditions [70,71].
5. Conclusions
Using the multi-omics approach, we showed how changes in lipid composition and
quantity are correlated with the changes in the liver proteome and phosphoproteome. To
the best of our knowledge, this is the first study to compare the relationships in terms of
proteins, phosphoproteins, and lipids in mouse liver under HFD-induced obesity. Free
fatty acids and ether glycerophosphocholines were negatively correlated with most of the
significantly dysregulated phosphosites, while other lipid classes were positively correlated in general. This suggests the importance of the lipid environment for the membrane
transporters and kinases functionality and highlights the relevance of future mechanistic
studies in this domain. Although several interesting relationships were discovered between
proteins and lipids, additional studies are necessary to determine the directionality of
these relationships. Although the changes at the site-specific phosphorylation level were
greater than the changes at the protein levels in the majority of cases, further studies will
determine the degree to which such changes are due to direct site-specific phosphorylation
changes that are independent of the changes at the relative protein abundances. One of
the limitations of this study is the fact that no targeted analysis was performed for proteins, phosphoproteins, and lipids that provides confirmatory identification and absolute
quantification data. Moreover, no mechanistic analyses were performed to determine the
directionality of the findings. However, these results offer new opportunities for improving
our understanding of the shift in liver metabolism of mice fed excess calories and provides
data that could be useful for future investigations that aim to find new treatments to control
the onset or slow down the progression of HFD induced hepatosteatosis.
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